Anakinra treatment in critically ill COVID-19 patients: a prospective ...
WEBDec 10, 2020 · Anakinra, a recombinant interleukin-1 receptor antagonist, is known to be effective in several hyperinflammatory diseases. We investigated the effects of anakinra on inflammatory parameters and clinical outcomes in critically ill, mechanically ventilated COVID-19 patients with clinical features of hyperinflammation.
Anakinra: a silver lining in COVID-19? - Critical Care
WEBOct 6, 2020 · Anakinra (IL-1α and IL-1β blocker) has shown greatly reduced mortality, need for invasive mechanical ventilation, and bettering oxygenation status in severe COVID-19 patients in smaller clinical studies [ 1 ]. Hence, anakinra might be effective in managing the severe pandemic state; more so, it is a well-tolerated molecule with no adverse ...
Fast recovery of cardiac function in PIMS-TS patients early using ...
WEBApr 7, 2021 · Second, the authors used anakinra in combination with high-dose methylprednisolone and intravenous immunoglobulins. Especially the use of high dosages of corticosteroids impedes proper assessment of the effects of anakinra. Third, anakinra treatment was tapered over a period of 5 weeks, to prevent an inflammatory rebound according to the authors.
Transitions of blood immune endotypes and improved outcome …
WEBMar 12, 2024 · Background Endotype classification may guide immunomodulatory management of patients with bacterial and viral sepsis. We aimed to identify immune endotypes and transitions associated with response to anakinra (human interleukin 1 receptor antagonist) in participants in the SAVE-MORE trial. Methods Adult patients hospitalized with radiological findings of PCR-confirmed severe pneumonia caused ...
Blocking IL-1 to prevent respiratory failure in COVID-19
WEBJul 18, 2020 · Anakinra is a bio-engineered form of the naturally occurring interleukin-1 receptor antagonist (IL-1ra) that blocks the action of interleukin-1 (Fig. 1). It is routinely used in patients with autoimmune and inflammatory disorders and MAS [44]. Anakinra has been used in several studies for sepsis and septic shock.
Diagnostic and management of life-threatening Adult-Onset Still …
WEBApr 11, 2018 · Background Adult-onset Still disease (AOSD) is a rare systemic inflammatory disorder. A few patients develop organ complications that can be life-threatening. Our objectives were to describe the disease course and phenotype of life-threatening AOSD, including response to therapy and long-term outcome. Methods A multicenter case series of intensive care medicine (ICU) patients with life ...
Targeting the host response in sepsis: current approaches and …
WEBDec 6, 2023 · Anakinra treatment provided higher odds for clinical improvement and lowered the 28-day mortality from 6.9 to 3.2%. SuPAR and MAS features illustrate the biological and clinical consequences of hyperinflammation such as coagulopathy and tissue damage . The results of the above studies therefore suggest that these classes of biomarkers may ...
Towards precision medicine for sepsis patients - Critical Care
WEBJan 12, 2017 · For instance, sepsis patients are more likely develop infections with opportunistic bacteria or fungi [7] and up to 40% of patients show positive viral polymerase chain reactions (PCRs) indicating reactivation of latent viruses [8]. Furthermore, in a post-mortem study [9], profound suppression of immune cell function was found in tissue from ...
Influence of therapeutic plasma exchange treatment on short-term ...
WEBJan 4, 2024 · Introduction The impact of therapeutic plasma exchange (TPE) on short-term mortality in adult patients with sepsis-induced organ dysfunction remains uncertain. The objective of the study is to assess the effect of adjunct TPE in this setting through a comprehensive literature review. Methods The National Library of Medicine’s Medline, Ovid (Embase), the Cochrane Library database and ...
Toxicities, intensive care management, and outcome of chimeric …
WEBMar 5, 2024 · IEC-HS management involves anakinra with or without corticosteroids. There are also concerns regarding potential adverse effects of corticosteroid therapy on CAR-T cell function and persistence, but most data suggest that short-term corticosteroids can be employed in the treatment of complications (including CRS/ICANS/IEC-HS) without a …